Copyright
©The Author(s) 2020.
World J Clin Cases. Sep 6, 2020; 8(17): 3718-3729
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3718
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3718
Table 3 Result in subgroup analysis (neutrophil/lymphocyte ratio)
| NLR ≥ 3 (n = 43) | NLR < 3 (n = 58) | P value | |||||
| GA (n = 24) | FFX (n = 19) | P value | GA (n = 30) | FFX (n = 28) | P value | ||
| PFS (mo) | 3.83 (3.19-4.47) | 7.60 (6.51-8.69) | 0.000b | ||||
| 3.40 (2.76-4.04) | 4.40 (2.65-6.15) | 0.676 | 8.10 (5.06-11.14) | 6.57 (3.38-9.76) | 0.008b | ||
| OS (mo) | 4.47 (2.80-6.14) | 10.87 (9.22-12.52) | 0.001b | ||||
| 3.87 (2.79-4.95) | 5.33 (3.87-6.80) | 0.648 | 12.87 (10.41-15.33) | 9.93 (5.91-13.95) | 0.002b | ||
- Citation: Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World J Clin Cases 2020; 8(17): 3718-3729
- URL: https://www.wjgnet.com/2307-8960/full/v8/i17/3718.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i17.3718